Sunitinib for advanced renal cell cancer
Chris CoppinBC Cancer Agency and University of British Columbia, Vancouver, CanadaAbstract: Renal cell cancer has been refractory to drug therapy in the large majority of patients. Targeted agents including sunitinib have been intensively evaluated in renal cell cancer over the past 5 years. Sunitin...
Guardado en:
Autor principal: | Chris Coppin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/0e56df7e3f4243d8b44f24ffdfe34e51 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
por: Chris Coppin
Publicado: (2010) -
Targeting of a platinum-bound sunitinib analog to renal proximal tubular cells
por: Dolman MEM, et al.
Publicado: (2012) -
MicroRNA modulation combined with sunitinib as a novel therapeutic strategy for pancreatic cancer
por: Passadouro M, et al.
Publicado: (2014) -
Multiparametric MRI for assessment of early response to neoadjuvant sunitinib in renal cell carcinoma.
por: Stephan Ursprung, et al.
Publicado: (2021) -
Repurposing ketoconazole as an exosome directed adjunct to sunitinib in treating renal cell carcinoma
por: Jacob W. Greenberg, et al.
Publicado: (2021)